For the relatives of participants with AR nDNA variants, despite the carrier risk (heterozygosity for a pathogenic variant), the risk of transmission remains low as compared to those with pathogenic AD nDNA and mtDNA variants and screening is mainly justified in the setting of consanguinity [25, 26]. This evidence concerns the gene AR and Alzheimer disease.